Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Montelukast in chronic lung allograft dysfunction after lung transplantation.

Vos R, Eynde RV, Ruttens D, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verbeken EK, Neyrinck AP, Van Raemdonck DE, Verleden GM; Leuven Lung Transplant Group.

J Heart Lung Transplant. 2019 May;38(5):516-527. doi: 10.1016/j.healun.2018.11.014. Epub 2018 Dec 6.

PMID:
30638839
2.

How resources determine pulmonary rehabilitation programs: A survey among Belgian chest physicians.

Janssens W, Corhay JL, Bogaerts P, Derom E, Frusch N, Dang DN, Kibanda J, Ruttens D, Thyrion L, Troosters T, Marchand E.

Chron Respir Dis. 2019 Jan-Dec;16:1479972318767732. doi: 10.1177/1479972318767732. Epub 2018 Apr 9.

3.

Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.

Ruttens D, Verleden SE, Demeyer H, Van Raemdonck DE, Yserbyt J, Dupont LJ, Vanaudenaerde BM, Vos R, Verleden GM.

PLoS One. 2018 Apr 6;13(4):e0193564. doi: 10.1371/journal.pone.0193564. eCollection 2018.

4.

High-dose vitamin D after lung transplantation: A randomized trial.

Vos R, Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Van Herck A, Sacreas A, Heigl T, Schaevers V, Van Raemdonck DE, Verbeken EK, Neyrinck AP, Dupont LJ, Yserbyt J, Vanaudenaerde BM, Verleden GM.

J Heart Lung Transplant. 2017 Aug;36(8):897-905. doi: 10.1016/j.healun.2017.03.008. Epub 2017 Mar 8.

PMID:
28365177
5.

Short- and Long-term Outcomes After Lung Transplantation From Circulatory-Dead Donors: A Single-Center Experience.

Ruttens D, Martens A, Ordies S, Verleden SE, Neyrinck AP, Vos R, Boada MC, Vanaudenaerde BM, Verleden GM, Van Raemdonck D.

Transplantation. 2017 Nov;101(11):2691-2694. doi: 10.1097/TP.0000000000001678.

PMID:
28207629
6.

Immunological diversity in phenotypes of chronic lung allograft dysfunction: a comprehensive immunohistochemical analysis.

Vandermeulen E, Lammertyn E, Verleden SE, Ruttens D, Bellon H, Ricciardi M, Somers J, Bracke KR, Van Den Eynde K, Tousseyn T, Brusselle GG, Verbeken EK, Verschakelen J, Emonds MP, Van Raemdonck DE, Verleden GM, Vos R, Vanaudenaerde BM.

Transpl Int. 2017 Feb;30(2):134-143. doi: 10.1111/tri.12882. Epub 2016 Dec 8.

7.

An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe.

Ruttens D, Verleden SE, Bijnens EM, Winckelmans E, Gottlieb J, Warnecke G, Meloni F, Morosini M, Van Der Bij W, Verschuuren EA, Sommerwerck U, Weinreich G, Kamler M, Roman A, Gomez-Olles S, Berastegui C, Benden C, Holm AM, Iversen M, Schultz HH, Luijk B, Oudijk EJ, Kwakkel-van Erp JM, Jaksch P, Klepetko W, Kneidinger N, Neurohr C, Corris P, Fisher AJ, Lordan J, Meachery G, Piloni D, Vandermeulen E, Bellon H, Hoffmann B, Vienneau D, Hoek G, de Hoogh K, Nemery B, Verleden GM, Vos R, Nawrot TS, Vanaudenaerde BM.

Eur Respir J. 2017 Jan 18;49(1). pii: 1600484. doi: 10.1183/13993003.00484-2016. Print 2017 Jan.

8.

Parametric Response Mapping of Bronchiolitis Obliterans Syndrome Progression After Lung Transplantation.

Verleden SE, Vos R, Vandermeulen E, Ruttens D, Bellon H, Heigl T, Van Raemdonck DE, Verleden GM, Lama V, Ross BD, Galbán CJ, Vanaudenaerde BM.

Am J Transplant. 2016 Nov;16(11):3262-3269. doi: 10.1111/ajt.13945. Epub 2016 Jul 29.

9.

Humoral immunity in phenotypes of chronic lung allograft dysfunction: A broncho-alveolar lavage fluid analysis.

Vandermeulen E, Verleden SE, Bellon H, Ruttens D, Lammertyn E, Claes S, Vandooren J, Ugarte-Berzal E, Schols D, Emonds MP, Van Raemdonck DE, Opdenakker G, Verleden GM, Vos R, Vanaudenaerde BM.

Transpl Immunol. 2016 Sep;38:27-32. doi: 10.1016/j.trim.2016.08.004. Epub 2016 Aug 22.

PMID:
27561239
10.

Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation.

Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Dubbeldam A, De Wever W, Dupont LJ, Van Raemdonck DE, Vanaudenaerde BM, Verleden GM, Benden C, Vos R.

J Heart Lung Transplant. 2016 Sep;35(9):1078-84. doi: 10.1016/j.healun.2016.03.022. Epub 2016 Apr 16.

PMID:
27212563
11.

Combined liver-thoracic transplantation: single-center experience with introduction of the 'Liver-first' principle.

Ceulemans LJ, Strypstein S, Neyrinck A, Verleden S, Ruttens D, Monbaliu D, De Leyn P, Vanhaecke J, Meyns B, Nevens F, Verleden G, Van Raemdonck D, Pirenne J.

Transpl Int. 2016 Jun;29(6):715-26. doi: 10.1111/tri.12781. Epub 2016 Apr 28.

12.

CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients.

Vercauteren IM, Verleden SE, McDonough JE, Vandermeulen E, Ruttens D, Lammertyn EJ, Bellon H, De Dycker E, Dooms C, Yserbyt J, Verleden GM, Vanaudenaerde BM, Wuyts WA.

Exp Lung Res. 2015;41(8):459-65. doi: 10.3109/01902148.2015.1073407.

PMID:
26381718
13.

Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.

Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Vanaudenaerde BM, Somers J, Schoonis A, Schaevers V, Van Raemdonck DE, Neyrinck A, Dupont LJ, Yserbyt J, Verleden GM, Vos R.

Am J Transplant. 2016 Jan;16(1):254-61. doi: 10.1111/ajt.13417. Epub 2015 Aug 4.

14.

BAL neutrophilia in azithromycin-treated lung transplant recipients: Clinical significance.

Vandermeulen E, Verleden SE, Ruttens D, Moelants E, Mortier A, Somers J, Bellon H, Piloni D, Dupont LJ, Van Raemdonck DE, Proost P, Schols D, Vos R, Verleden GM, Vanaudenaerde BM.

Transpl Immunol. 2015 Sep;33(1):37-44. doi: 10.1016/j.trim.2015.07.001. Epub 2015 Jul 11.

PMID:
26168736
15.

Linking clinical phenotypes of chronic lung allograft dysfunction to changes in lung structure.

Verleden SE, Vasilescu DM, McDonough JE, Ruttens D, Vos R, Vandermeulen E, Bellon H, Geenens R, Verbeken EK, Verschakelen J, Van Raemdonck DE, Wuyts WA, Sokolow Y, Knoop C, Cooper JD, Hogg JC, Verleden GM, Vanaudenaerde BM.

Eur Respir J. 2015 Nov;46(5):1430-9. doi: 10.1183/09031936.00010615. Epub 2015 Jun 25.

16.

Interleukin-17 receptor polymorphism predisposes to primary graft dysfunction after lung transplantation.

Somers J, Ruttens D, Verleden SE, Vandermeulen E, Piloni D, Wauters E, Lambrechts D, Vos R, Verleden GM, Vanaudenaerde B, van Raemdonck DE.

J Heart Lung Transplant. 2015 Jul;34(7):941-9. doi: 10.1016/j.healun.2015.03.009. Epub 2015 Mar 26.

PMID:
25935436
17.

Role of genetics in lung transplant complications.

Ruttens D, Vandermeulen E, Verleden SE, Bellon H, Vos R, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden GM.

Ann Med. 2015 Mar;47(2):106-15. doi: 10.3109/07853890.2015.1004359. Epub 2015 Mar 13. Review.

PMID:
25766881
18.

Restrictive chronic lung allograft dysfunction: Where are we now?

Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden G, Vos R.

J Heart Lung Transplant. 2015 May;34(5):625-30. doi: 10.1016/j.healun.2014.11.007. Epub 2014 Nov 11.

PMID:
25577564
19.

Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort.

Ameye H, Ruttens D, Benveniste O, Verleden GM, Wuyts WA.

Transplant Proc. 2014 Nov;46(9):3147-53. doi: 10.1016/j.transproceed.2014.09.163.

PMID:
25420846
20.

Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation.

Vos R, Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Neyrinck A, Van Raemdonck DE, Yserbyt J, Dupont LJ, Verbeken EK, Moelants E, Mortier A, Proost P, Schols D, Cox B, Verleden GM, Vanaudenaerde BM.

Am J Transplant. 2014 Dec;14(12):2736-48. doi: 10.1111/ajt.12942. Epub 2014 Nov 13.

21.

A decade of extended-criteria lung donors in a single center: was it justified?

Somers J, Ruttens D, Verleden SE, Cox B, Stanzi A, Vandermeulen E, Vos R, Vanaudenaerde BM, Verleden GM, Van Veer H, Coosemans W, Decaluwe H, Nafteux P, De Leyn P, Van Raemdonck DE.

Transpl Int. 2015 Feb;28(2):170-9. doi: 10.1111/tri.12470. Epub 2014 Oct 30.

22.

Pregnancy after heart and lung transplantation.

Vos R, Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Vanaudenaerde BM, Verleden GM.

Best Pract Res Clin Obstet Gynaecol. 2014 Nov;28(8):1146-62. doi: 10.1016/j.bpobgyn.2014.07.019. Epub 2014 Aug 6.

PMID:
25179291
23.

Differential cytokine, chemokine and growth factor expression in phenotypes of chronic lung allograft dysfunction.

Verleden SE, Ruttens D, Vos R, Vandermeulen E, Moelants E, Mortier A, Van Raemdonck DE, Proost P, Schols D, Verleden GM, Vanaudenaerde BM.

Transplantation. 2015 Jan;99(1):86-93. doi: 10.1097/TP.0000000000000269.

PMID:
25050473
24.

Body mass index in lung transplant candidates: a contra-indication to transplant or not?

Ruttens D, Verleden SE, Vandermeulen E, Vos R, van Raemdonck DE, Vanaudenaerde BM, Verleden GM.

Transplant Proc. 2014 Jun;46(5):1506-10. doi: 10.1016/j.transproceed.2014.04.004.

PMID:
24935321
25.

Genetic variation in immunoglobulin G receptor affects survival after lung transplantation.

Ruttens D, Verleden SE, Goeminne PC, Vandermeulen E, Wauters E, Cox B, Vos R, Van Raemdonck DE, Lambrechts D, Vanaudenaerde BM, Verleden GM.

Am J Transplant. 2014 Jul;14(7):1672-7. doi: 10.1111/ajt.12745. Epub 2014 May 6.

26.

Genetic variation in caveolin-1 affects survival after lung transplantation.

Vandermeulen E, Ruttens D, Verleden SE, Vos R, Van Raemdonck DE, Kastelijn EA, Wauters E, Lambrechts D, Nawrot TS, Cox B, Verleden GM, Vanaudenaerde BM.

Transplantation. 2014 Aug 15;98(3):354-9. doi: 10.1097/TP.0000000000000058.

PMID:
24621537
27.

Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation.

Verleden SE, de Jong PA, Ruttens D, Vandermeulen E, van Raemdonck DE, Verschakelen J, Vanaudenaerde BM, Verleden GM, Vos R.

J Heart Lung Transplant. 2014 Mar;33(3):270-7. doi: 10.1016/j.healun.2013.12.011. Epub 2013 Dec 17.

PMID:
24461432
28.

Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis.

Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ.

Respir Med. 2014 Feb;108(2):287-96. doi: 10.1016/j.rmed.2013.12.015. Epub 2014 Jan 8.

29.

The site and nature of airway obstruction after lung transplantation.

Verleden SE, Vasilescu DM, Willems S, Ruttens D, Vos R, Vandermeulen E, Hostens J, McDonough JE, Verbeken EK, Verschakelen J, Van Raemdonck DE, Rondelet B, Knoop C, Decramer M, Cooper J, Hogg JC, Verleden GM, Vanaudenaerde BM.

Am J Respir Crit Care Med. 2014 Feb 1;189(3):292-300. doi: 10.1164/rccm.201310-1894OC.

PMID:
24354907
30.

Genetic variation in interleukin-17 receptor A is functionally associated with chronic rejection after lung transplantation.

Ruttens D, Wauters E, Kiciński M, Verleden SE, Vandermeulen E, Vos R, Van Raemdonck DE, Nawrot TS, Lambrechts D, Verleden GM, Vanaudenaerde BM.

J Heart Lung Transplant. 2013 Dec;32(12):1233-40. doi: 10.1016/j.healun.2013.09.008.

PMID:
24263024
31.

Elevated bronchoalveolar lavage eosinophilia correlates with poor outcome after lung transplantation.

Verleden SE, Ruttens D, Vandermeulen E, van Raemdonck DE, Vanaudenaerde BM, Verleden GM, Vos R.

Transplantation. 2014 Jan 15;97(1):83-9. doi: 10.1097/TP.0b013e3182a6bae2.

PMID:
24157472
32.

Pirfenidone: a potential new therapy for restrictive allograft syndrome?

Vos R, Verleden SE, Ruttens D, Vandermeulen E, Yserbyt J, Dupont LJ, Van Raemdonck DE, De Raedt N, Gheysens O, De Jong PA, Verleden GM, Vanaudenaerde BM.

Am J Transplant. 2013 Nov;13(11):3035-40. doi: 10.1111/ajt.12474. Epub 2013 Sep 18.

33.

Smoking resumption after lung transplantation: standardised screening and importance for long-term outcome.

Ruttens D, Verleden SE, Goeminne PC, Poels K, Vandermeulen E, Godderis L, Van Raemdonck DE, Vanaudenaerde BM, Vanoirbeek J, Vos R, Verleden GM.

Eur Respir J. 2014 Jan;43(1):300-3. doi: 10.1183/09031936.00141113. Epub 2013 Aug 29. No abstract available.

34.

Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS).

Verleden SE, Vandermeulen E, Ruttens D, Vos R, Vaneylen A, Dupont LJ, Van Raemdonck DE, Vanaudenaerde BM, Verleden GM.

Semin Respir Crit Care Med. 2013 Jun;34(3):352-60. doi: 10.1055/s-0033-1348463. Epub 2013 Jul 2. Review.

PMID:
23821509
35.

Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?

Verleden SE, Ruttens D, Vandermeulen E, Vaneylen A, Dupont LJ, Van Raemdonck DE, Verleden GM, Vanaudenaerde BM, Vos R.

Transplantation. 2013 May 15;95(9):1167-72. doi: 10.1097/TP.0b013e318286e076.

PMID:
23425818
36.

Involvement of interleukin-17 during lymphocytic bronchiolitis in lung transplant patients.

Verleden SE, Vos R, Vandermeulen E, Ruttens D, Vaneylen A, Dupont LJ, Verbeken EK, Verleden GM, Van Raemdonck DE, Vanaudenaerde BM.

J Heart Lung Transplant. 2013 Apr;32(4):447-53. doi: 10.1016/j.healun.2012.12.016. Epub 2013 Feb 14.

PMID:
23415729
37.

Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection.

Vos R, Vanaudenaerde BM, Verleden SE, Ruttens D, Vaneylen A, Van Raemdonck DE, Dupont LJ, Verleden GM.

Transplantation. 2012 Jul 27;94(2):101-9. doi: 10.1097/TP.0b013e31824db9da. Review.

PMID:
22461039
38.

Vitamin D deficiency in lung transplant patients: is it important?

Verleden SE, Vos R, Geenens R, Ruttens D, Vaneylen A, Dupont LJ, Verleden GM, van Raemdonck DE, Vanaudenaerde BM.

Transplantation. 2012 Jan 27;93(2):224-9. doi: 10.1097/TP.0b013e31823d98bc.

PMID:
22134370
39.

Inflammation of unknown origin versus fever of unknown origin: two of a kind.

Vanderschueren S, Del Biondo E, Ruttens D, Van Boxelaer I, Wauters E, Knockaert DD.

Eur J Intern Med. 2009 Jul;20(4):415-8. doi: 10.1016/j.ejim.2009.01.002. Epub 2009 Feb 1.

PMID:
19524186

Supplemental Content

Loading ...
Support Center